Your session is about to expire
← Back to Search
Imaging Techniques for Acute Myeloid Leukemia
Study Summary
This trial is looking at using PET/MRI, 18F-FDG PET/CT, and whole body MRI to detect extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 18 years old.I have been recently diagnosed with AML or APL.I am a woman who can have children and have a negative pregnancy test.My kidney function is reduced with a creatinine clearance below 60.I have received more than minimal treatment for leukemia.My AML or APL cancer has returned after treatment.My leukemia has spread outside the bone marrow.I weigh more than 400 pounds.My diabetes is not under control.
- Group 1: Diagnostic (18F-FDG PET/CT, whole body PET/MRI)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA greenlit Diagnostic (18F-FDG PET/CT, whole body PET/MRI) for general use?
"The safety of this diagnostic technique has been measured at a score of 1, as it is currently only in the preliminary stages and lacks substantial evidence to support its efficacy."
Are there any vacancies open to participate in this research?
"According to the information hosted on clinicaltrials.gov, recruitment for this trial has been suspended at present. It was initially listed on May 2nd 2016 and last updated March 28th 2023, but there are still 1577 other studies that require participants."
What health conditions can be observed with Diagnostic (18F-FDG PET/CT, whole body PET/MRI) imaging?
"18F-FDG PET/CT and whole body PET/MRI are frequently used to diagnose seizures, epilepsy. They can also be utilized in the diagnosis of coronary artery disease (CAD), cancer, and positron emission tomography (PET)."
What other research has been conducted with regards to Diagnostic (18F-FDG PET/CT, whole body PET/MRI) imaging?
"Currently, 27 trials are researching Diagnostic (18F-FDG PET/CT, whole body PET/MRI). One of these studies is in its final stage. With a majority located in Wuhan, Hubei province, 30 different sites have begun clinical trial for this treatment."
What is the cap for enrollment in this experimental program?
"This trial is not presently accepting patients, as the last update was registered on March 28th 2023. If you are nonetheless looking for other studies to participate in, there are 1550 clinical trials recruiting individuals with acute promyelocytic leukemia and 27 research projects actively admitting participants that involve Diagnostic (18F-FDG PET/CT, whole body PET/MRI)."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger